Abstract
L-084 (a prodrug of LJC 11,036 [L-036]) is a new oral carbapenem. Here we compared the in vitro and in vivo antibacterial activities of L-036 with those of imipenem, faropenem, ceditoren-pivoxil, cefdinir, amoxicillin, and levofloxacin. The MICs at which 90% of the isolates were inhibited of L-036 against methicillin-susceptible staphylococci, Streptococcus pneumoniae including penicillin-resistant organisms, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae including ampicillin-resistant organisms, Legionella pneumophila, and Moraxella catarrhalis were equal to or less than 1 μg/ml. In pharmacokinetics studies of L-084 in lungs of mice, the maximum concentration in serum, half-life, and area under the concentration-time curve of this drug were 9.09 μg/g of tissue, 6.18 h, and 31.0 μg · h/ml, respectively. In murine respiratory infection models of penicillin-susceptible and -resistant S. pneumoniae and H. influenzae, the efficacies of L-084 were better than those of reference drugs. Our results indicate that the in vitro high potency and good distribution in the lungs might be the underlying mechanisms of its efficacy in the murine model of pneumonia.
Carbapenems such as imipenem, meropenem, and panipenem, which are commercially available parenteral drugs, have broad-spectrum activity against both gram-positive and gram-negative bacteria. To date, there are many types of oral antimicrobial agents such as β-lactams, fluoroquinolones, and penems with broad antibacterial activities. Recently, there has been an increase in the incidence of community-acquired respiratory tract infections caused by penicillin-resistant Streptococcus pneumoniae, penicillinase-producing Haemophilus influenzae, and β-lactamase-nonproducing ampicillin-resistant H. influenzae (3, 13, 18). In addition, the incidence of infections caused by fluoroquinolone-resistant organisms also seems to have increased (1, 5, 14). These conditions highlight the need for novel antimicrobial agents active against these problematic pathogens. At present, various oral carbapenems such as GV118819X, CS-834, DZ-2640, and CL191,121 remain under development (12, 15, 16, 19, 20).
L-084, pivaloyloxymethyl(4R, 5S, 6S)-6-[(R)-1-hydroxyethyl]-4-methy-7-oxo-3-{[1-(1,3-thiazolin-2-yl)azetidin-3-yl]thio]}-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate, is a novel oral carbapenem synthesized at the Medical Research Laboratories, Lederle (Japan), Ltd., Saitama, Japan. In the study described here, we evaluated the in vitro antibacterial properties of LJC 11,036 (L-036) and the in vivo activities of L-084 (a prodrug of L-036) by using models of murine bronchopneumonia caused by H. influenzae and pneumonia caused by S. pneumoniae. We also compared the potency of this drug with those of faropenem, imipenem, levofloxacin, cefditoren-pivoxil (a prodrug of cefditoren), cefdinir, and amoxicillin.
MATERIALS AND METHODS
Antimicrobial agents.
The following antimicrobial agents, used in this study, were obtained from the indicated sources: L-036 and L-084, Wyeth Lederle Japan, Tokyo, Japan; faropenem, Suntory, Tokyo, Japan; imipenem, Banyu Pharmaceutical Co., Tokyo, Japan; levofloxacin, Daiichi Pharmaceutical Co., Tokyo, Japan; cefditoren and cefditoren-pivoxil, Meiji Seika Co., Tokyo, Japan; cefdinir and amoxicillin, Fujisawa Pharmaceutical Co., Osaka, Japan.
Microorganisms.
The clinical isolates tested in this study were obtained from hospitals in several areas of Japan during 1995 and 1997. All organisms had previously been identified by routine laboratory methods and had been stored at −80°C.
In vitro susceptibility tests.
The MICs of various antimicrobial agents for nonfastidious organisms were determined by the broth microdilution method in 0.1-ml volumes of cation-adjusted Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) (8). For fastidious organisms such as Streptococcus spp., Enterococcus spp., and Moraxella catarrharis, cation-adjusted Mueller-Hinton broth supplemented with 5% lysed horse blood was used (9). For Legionella pneumophila, the MICs were determined by the microdilution method using N-(acetamide)-2-amino-ethanesulfonic acid-buffered yeast extract broth supplemented with 0.1% α-ketoglutaric acid, 0.04% l-cysteine, and 0.025% iron(III) diphosphate and adjusted to a final pH of 6.9. For H. influenzae, cation-adjusted Mueller-Hinton broth was supplemented with 5% lysed horse blood plus 5 mg of yeast extract (Oxoid, Hampshire, United Kingdom) per ml and 15 μg of NAD (Sigma Chemical Co., St. Louis, Mo.). For all strains except L. pneumophila, incubation was carried out for 18 to 24 h at 35°C. For L. pneumophila, incubation was performed for 116 h. Microdilution plates were inoculated with an automatic pin inoculator (MIC-2000; Dynatech Laboratories Inc., Alexandria, Va.) so that the final inoculum was approximately 5 × 105 CFU/ml. The MIC was defined as the lowest concentration of antimicrobial agent resulting in the complete inhibition of visible bacterial growth.
In vivo activity.
The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Toho University School of Medicine. Four-week-old male Slc/ICR mice (weight, 18 to 20 g; SLC Japan Inc., Shizuoka, Japan) and 4-week-old male CBA/J mice (Charles River Japan, Shizuoka, Japan) were used. CBA/J mice are susceptible to intranasal infection caused by penicillin-resistant streptococcal pneumonia (17). The bacterial suspension was prepared as previously reported (20). S. pneumoniae organisms were inoculated in Todd-Hewitt broth (Difco) supplemented with 30% horse serum, and the mixture was incubated at 35°C until the culture became turbid to the naked eye. When the bacteria were in the late logarithmic phase, they were harvested by centrifugation at 2,000 × g for 10 min at 4°C. The organisms were suspended in saline. Mice were anesthetized with ketamine-xylazine and then infected by intranasal instillation of 0.05 ml of S. pneumoniae TUH39 (MIC of penicillin G, 0.016 μg/ml; 9.6 × 107 CFU/ml) or S. pneumoniae TUM741 (MIC of penicillin G, 1.0 μg/ml; 5.1 × 105 CFU/ml). Since 4-week-old male ICR mice (body weight, about 20 g) were the most susceptible to intranasal infection caused by H. influenzae among test strains in preliminary experiments, mice of this strain were used in H. influenzae infections. An overnight culture of H. influenzae TMS8 was inoculated into brain heart infusion broth (Difco) supplemented with hemin and NAD, and the culture was incubated at 35°C for 3 h. The organisms in the culture were harvested by centrifugation and were suspended in RPMI 1640 medium to prepare cultures similar to the original. This bacterial suspension was added to MFL cell monolayers, and the monolayers were incubated at 35°C for 1 h with gentle shaking (10). Free-floating bacteria were removed and washed three times with saline. Then, cell-bound organisms (CBOs) were removed from the flask and suspended in RPMI 1640 medium. Three days after treatment with formalin, mice were anesthetized with ketamine-xylazine and then infected by intranasal instillation of 0.05 ml of H. influenzae TUM8 CBOs (4.2 × 105 CFU/ml). The inocula of S. pneumoniae TUH39 organisms caused 100% mortality in untreated animals at 72 to 116 h after infection. Antimicrobial drugs were administered orally once at 20 h after intranasal instillation of S. pneumoniae TUH39 organisms. The total number of surviving mice at each dose was recorded on day 7 after infection. The 50% effective dose (ED50) of each drug was calculated by the probit method. Oral administration of drugs commenced 2 days after infection and was continued for 3 days, with the drugs being given once a day, twice a day (at 12-h intervals), or three times a day (at 6-h intervals) for S. pneumoniae TUM741 and H. influenzae TUM8 infections. Animals were sacrificed 20 h after the last administration of the test drug (in order to minimize the influence of the administered drug), and the infected tissues were dissected and homogenized. The number of viable organisms (number of CFU per lung) was determined by agar plating. Evaluation of efficacy was based on the proportional reduction of bacterial counts in the infected tissues of treated animals compared with those in infected tissues of untreated animals. The statistical significance of the observed differences was determined by the Mann-Whitney U test.
Pharmacokinetic studies with mice.
One day after infection with S. pneumoniae TUH39, groups of three mice each orally received L-084 at a single dose of 50 mg/kg of body weight because this dosage was used for evaluation of L-084 in murine respiratory infection by S. pneumoniae or H. influenzae. Samples of heart blood as well as lung tissues were obtained 5, 15, and 30 min and 1, 2, 4, 6, and 24 h after drug administration. The lungs were briefly washed with saline in order to minimize contamination with blood. The levels of L-036 in serum and tissues were determined by a paper disk method, with Staphylococcus aureus Terajima as the indicator organism for L-036; the indicator organisms were incorporated into the medium (heart infusion agar; Difco).
RESULTS
In vitro antibacterial activity.
Table 1 compares the in vitro activities of L-036 to those of other drugs tested against a variety of clinical isolates. L-036 exhibited high potency against methicillin-susceptible isolates of both S. aureus and Staphylococcus epidermidis, but the activities of L-036 against methicillin-resistant staphylococci were lower than those against methicillin-susceptible staphylococci. L-036 was more potent against penicillin-susceptible and -resistant S. pneumoniae than all compared drugs by a factor of 4 or more. For Enterococcus faecalis, L-36 was more potent than faropenem, levofloxacin, cefditoren, and cefdinir but was similar to imipenem and less active than amoxicillin. For both Escherichia coli and Klebsiella pneumoniae, L-036 was twice or more as active as all reference drugs. L-036 was more active against H. influenzae than faropenem, imipenem, cefdinir, and amoxicillin but was less active than levofloxacin and cefditoren. For L. pneumophila and M. catarrhalis, L-036 was the drug showing the most potent activity.
TABLE 1.
Comparative in vitro activities of L-036 and reference drugs against clinical isolates
| Organism (no. of strains) | Drug | MIC (μg/ml)a
|
||
|---|---|---|---|---|
| Range | 50% | 90% | ||
| Staphylococcus aureus | ||||
| Methicillin-susceptible strains (43) | L-036 | ≤0.063 | ≤0.063 | ≤0.063 |
| Faropenem | ≤0.063–0.25 | 0.125 | 0.25 | |
| Imipenem | ≤0.063 | ≤0.063 | ≤0.063 | |
| Levofloxacin | 0.125–1 | 0.25 | 0.5 | |
| Cefditoren | 0.5–4 | 1 | 1 | |
| Cefdinir | 0.25–4 | 0.5 | 0.5 | |
| Amoxicillin | 0.25–64 | 4 | 16 | |
| Methicillin-resistant strains (39)b | L-036 | ≤0.063–8 | 4 | 8 |
| Faropenem | 0.125–>128 | 128 | >128 | |
| Imipenem | 0.063–64 | 32 | 64 | |
| Levofloxacin | 0.125–>128 | 8 | 128 | |
| Cefditoren | 4–>128 | 64 | 128 | |
| Cefdinir | 0.125–>128 | 64 | 128 | |
| Amoxicillin | 8–128 | 64 | 64 | |
| Staphylococcus epidermidis | ||||
| Methicillin-susceptible strains (34) | L-036 | ≤0.063–1 | ≤0.063 | 0.125 |
| Faropenem | ≤0.063–0.5 | 0.125 | 0.5 | |
| Imipenem | ≤0.063–0.125 | ≤0.063 | 0.125 | |
| Levofloxacin | 0.125–8 | 0.25 | 4 | |
| Cefditoren | 0.125–2 | 0.5 | 2 | |
| Cefdinir | ≤0.063–2 | 0.125 | 1 | |
| Amoxicillin | 0.125–8 | 0.5 | 2 | |
| Methicillin-resistant strains (30)b | L-036 | 0.5–8 | 2 | 8 |
| Faropenem | ≤0.063–>128 | 2 | >128 | |
| Imipenem | 0.25–64 | 4 | 64 | |
| Levofloxacin | 0.25–128 | 4 | 16 | |
| Cefditoren | 2–128 | 16 | 64 | |
| Cefdinir | 0.125–>128 | 16 | 128 | |
| Amoxicillin | 1–64 | 8 | 32 | |
| Streptococcus pneumoniae | ||||
| Penicillin-susceptible strains (66) | L-036 | 0.0005–0.032 | 0.002 | 0.032 |
| Faropenem | 0.004–0.25 | 0.008 | 0.25 | |
| Imipenem | 0.002–0.25 | 0.008 | 0.125 | |
| Levofloxacin | 0.25–2 | 0.5 | 1 | |
| Cefditoren | 0.008–0.5 | 0.063 | 0.5 | |
| Cefdinir | 0.016–8 | 0.25 | 4 | |
| Amoxicillin | 0.008–0.5 | 0.032 | 0.5 | |
| Penicillin-resistant strains (32)c | L-036 | 0.032–0.5 | 0.063 | 0.125 |
| Faropenem | 0.25–4 | 0.5 | 2 | |
| Imipenem | 0.25–2 | 0.25 | 1 | |
| Levofloxacin | 0.5–1 | 1 | 1 | |
| Cefditoren | 0.25–4 | 0.5 | 1 | |
| Cefdinir | 2–64 | 8 | 16 | |
| Amoxicillin | 1–8 | 2 | 4 | |
| Enterococcus faecalis (35) | L-036 | 0.25–2 | 0.5 | 2 |
| Faropenem | 0.5–8 | 1 | 4 | |
| Imipenem | 8–>128 | 128 | >128 | |
| Levofloxacin | 1–64 | 1 | 64 | |
| Cefditoren | 0.5–>128 | 32 | >128 | |
| Cefdinir | 0.5–>128 | 4 | 64 | |
| Amoxicillin | 0.5–1 | 0.5 | 1 | |
| Enterococcus faecium (45) | L-036 | 2–>128 | 64 | 128 |
| Faropenem | 4–>128 | 128 | >128 | |
| Imipenem | 8–>128 | 128 | >128 | |
| Levofloxacin | 1–128 | 16 | 64 | |
| Cefditoren | 64–>128 | >128 | >128 | |
| Cefdinir | 64–>128 | >128 | >128 | |
| Amoxicillin | 0.5–>128 | 64 | 64 | |
| Escherichia coli (42) | L-036 | ≤0.063 | ≤0.063 | ≤0.063 |
| Faropenem | 0.125–2 | 0.5 | 0.5 | |
| Imipenem | ≤0.063–0.25 | 0.125 | 0.125 | |
| Levofloxacin | ≤0.063–64 | ≤0.063 | 8 | |
| Cefditoren | ≤0.063–1 | 0.25 | 0.5 | |
| Cefdinir | ≤0.063–1 | 0.125 | 0.5 | |
| Amoxicillin | 0.5–>128 | 4 | >128 | |
| Klebsiella pneumoniae (34) | L-036 | ≤0.063–0.5 | ≤0.063 | ≤0.063 |
| Faropenem | 0.25–4 | 0.5 | 0.5 | |
| Imipenem | 0.125–0.5 | 0.25 | 0.25 | |
| Levofloxacin | ≤0.063–4 | ≤0.063 | 0.25 | |
| Cefditoren | ≤0.063–64 | 0.25 | 0.5 | |
| Cefdinir | ≤0.063–128 | 0.125 | 0.25 | |
| Amoxicillin | 1–>128 | 64 | >128 | |
| Haemophilus influenzae (38) | L-036 | ≤0.063–0.5 | ≤0.063 | 0.25 |
| Faropenem | 0.125–4 | 0.5 | 1 | |
| Imipenem | 0.25–16 | 1 | 4 | |
| Levofloxacin | ≤0.063 | ≤0.063 | ≤0.063 | |
| Cefditoren | ≤0.063–0.25 | ≤0.063 | ≤0.063 | |
| Cefdinir | 0.25–4 | 0.5 | 2 | |
| Amoxicillin | 0.5–32 | 0.5 | 32 | |
| Legionella pneumophila (11) | L-036 | ≤0.063 | ≤0.063 | ≤0.063 |
| Faropenem | ≤0.063 | ≤0.063 | ≤0.063 | |
| Imipenem | ≤0.063 | ≤0.063 | ≤0.063 | |
| Levofloxacin | ≤0.063 | ≤0.063 | ≤0.063 | |
| Cefditoren | 0.25–16 | 8 | 16 | |
| Cefdinir | 0.25–8 | 8 | 8 | |
| Amoxicillin | ≤0.063–1 | 0.5 | 1 | |
| Moraxella catarrhalis (34) | L-036 | ≤0.063 | ≤0.063 | ≤0.063 |
| Faropenem | ≤0.063–1 | 0.25 | 0.5 | |
| Imipenem | ≤0.063–0.125 | ≤0.063 | ≤0.063 | |
| Levofloxacin | ≤0.063 | ≤0.063 | ≤0.063 | |
| Cefditoren | ≤0.063–0.5 | 0.25 | 0.5 | |
| Cefdinir | 0.125–0.5 | 0.25 | 0.5 | |
| Amoxicillin | ≤0.063–8 | 2 | 4 | |
50% and 90%, MICs at which 50 and 90% of isolates were inhibited, respectively.
Oxacillin MIC, ≥4 μg/ml.
Amoxicillin MIC, ≥one μg/ml.
In vivo efficacy in mice.
The in vivo activity of L-036 against penicillin-susceptible S. pneumoniae TUH39 was only twice that of faropenem but higher than those of other reference drugs (Table 2). Against respiratory tract infections induced by instillation of this strain, L-084 alone was very potent and effective. When infection was caused by penicillin-resistant S. pneumoniae TUM741, the mean number of bacteria recovered from the lungs of untreated mice was 7.36 ± 1.19 log CFU/lung (Table 3). In comparison, the number in mice treated with L-084 at a dosage of 50 mg/kg three times a day for 3 days was below the detection limits. On the other hand, treatment with 50 mg of amoxicillin/kg significantly reduced the number of recovered bacteria compared to that recovered from untreated animals and animals treated with faropenem, cefditoren-pivoxil, and cefdinir at the corresponding dose. Moreover, treatment with L-084 at a dose of 10 mg/kg resulted in a significant reduction in the number of bacteria compared with that in the lungs of untreated animals and animals treated with faropenem, cefditoren-pivoxil, cefdinir, and amoxicillin at the corresponding dose.
TABLE 2.
Therapeutic efficacy of L-084 and reference drugs in murine respiratory tract infections caused by penicillin-susceptible S. pneumoniae TUH39a
| Antimicrobial agent | MICb (mg/ml) | ED50c(95% confidence limits) (mg/kg) |
|---|---|---|
| L-084 | 0.0005 | 1.95 (1.34–3.00) |
| Faropenem | 0.001 | >20 |
| Cefdinir | 0.125 | >20 |
| Cefditoren-pivoxil | 0.016 | >20 |
| Amoxicillin | 0.004 | >20 |
The challenge dose was 1.5 × 106 CFU/mouse, administered by intranesal instillation.
Broth microdilution method (inoculum size: 105 CFU/ml).
ED50s were calculated by the probit method based on the survival rate at 7 days after infection.
TABLE 3.
Therapeutic efficacy of L-084 and reference drugs against murine respiratory tract infection caused by penicillin-resistant S. pneumoniae TUM741
| Drug | MIC (μg/ml) | Dosed (mg/kg) | Log CFU/lung (mean ± SD) |
|---|---|---|---|
| Control | 7.36 ± 1.19 | ||
| L-084 | 0.032 | 50 | BDa |
| 10 | 2.53 ± 0.48b | ||
| Faropenem | 0.25 | 50 | 6.72 ± 1.21 |
| 10 | 7.90 ± 2.11 | ||
| Cefditoren-pivoxil | 0.25 | 50 | 6.93 ± 0.75 |
| 10 | 8.42 ± 0.56 | ||
| Cefdinir | 2.0 | 50 | 6.74 ± 0.69 |
| 10 | 7.45 ± 1.03 | ||
| Amoxicillin | 1.0 | 50 | 4.26 ± 0.70c |
| 10 | 7.21 ± 0.72 |
BD, below the lower limit of detection.
P < 0.01 versus control and faropenem-, cefditoren-pivoxil-, cefdinir-, and amoxicillin-treated groups at the corresponding dose.
P < 0.05 versus control and faropenem-, cefditoren-pivoxil-, and cefdinir-treated groups at the corresponding dose.
Drugs were administered orally three times a day for 3 days.
When infection was induced by instillation of penicillinase-nonproducing H. influenzae TUM8, the mean number of bacteria recovered from the lungs of untreated mice was 6.97 ± 1.01 or 6.91 ± 0.97 log CFU/lung (Table 4). Treatment with L-084, cefditoren-pivoxil, and amoxicillin at a dose of 20 mg/kg led to significant reductions (P < 0.05) in the numbers of organisms in the lungs compared with those from untreated animals and animals treated with faropenem and cefdinir at the corresponding dose. In addition, treatment with L-084 and cefditoren-pivoxil at a dose of 4 mg/kg resulted in significant reductions (P < 0.01) in the numbers of organisms compared to those from untreated animals and animals treated with faropenem, cefdinir, and amoxicillin at the corresponding dose.
TABLE 4.
Therapeutic efficacy of L-084 and reference drugs against murine respiratory tract infection caused by H. influenzae TUM8
| Drug | MIC (mg/ml) | Dosec (mg/kg) | Log CFU/lung (mean ± SD) |
|---|---|---|---|
| Control | 20 | 6.97 ± 1.01 | |
| 4 | 6.91 ± 0.97 | ||
| L-084 | 0.016 | 20 | 2.28 ± 0.01a |
| 4 | 2.57 ± 0.68b | ||
| Faropenem | 0.25 | 20 | 5.32 ± 1.75 |
| 4 | 5.25 ± 1.12 | ||
| Cefditoren-pivoxil | 0.002 | 20 | 2.28 ± 0.01a |
| 4 | 3.40 ± 0.43b | ||
| Cefdinir | 0.25 | 20 | 4.72 ± 0.50 |
| 4 | 6.09 ± 0.76 | ||
| Amoxicillin | 0.25 | 20 | 3.72 ± 1.27a |
| 4 | 5.95 ± 0.63 |
P < 0.05 versus control and faropenem- and cefdinir-treated groups at the corresponding dose.
P < 0.01 versus control and faropenem-, cefdinir-, and amoxicillin-treated groups at the corresponding dose.
Drugs were administered orally twice a day for 3 days.
Effect of frequency of drug administration on the efficacy of L-084.
In mice infected with pneumonia caused by penicillin-resistant S. pneumoniae TUM741, the number of organisms in the lungs of those treated with L-084 three times a day (6-h intervals), with each dose being 5 mg/kg (total daily dose, 15 mg/kg), was 2.40 ± 1.26 log CFU/lung. The numbers in mice treated with the same daily dose but administered twice a day (12-h intervals, each 7.5 mg/kg) or once a day (15 mg/kg) were 2.13 ± 1.06 and 3.06 ± 0.74 log CFU/lung, respectively. There was no significant difference in the efficacy of the drug between these three regimens.
Pharmacokinetics in pneumonic mice.
When the concentrations of L-036 in the plasma and lungs of mice infected with S. pneumoniae TUH39 were calculated, the maximum concentrations of L-036 in the lungs and serum (Cmax) were 9.03 μg/g of tissue and 51.24 μg/ml, respectively. The areas under the concentration-time curve (AUC) for L-084 in the lungs and serum were 31.0 and 142.2 μg × h/ml, respectively. The half-lives (t1/2) of L-084 in the lungs and serum were 6.18 and 3.88 h, respectively.
DISCUSSION
Hikita et al. (6) reported that L-036 was more potent than imipenem, faropenem, and cefdinir against the main organisms of respiratory and urinary tract infections such as those due to S. pneumoniae, Streptococcus pyogenes, H. influenzae, K. pneumoniae, M. catarrhalis, and E. coli. The present results were similar to those from the above study and indicated that L-036 concentration was maintained at ≥1 μg/g in the lungs for at least 6 h after oral administration of 50 mg/kg. In addition, the MICs of L-036 at which 90% of the isolates of methicillin-susceptible staphylococci, S. pneumoniae including penicillin-resistant organisms, E. coli, K. pneumoniae, H. influenzae, L. pneumophila, and M. catarrhalis were inhibited were <1 μg/ml. S. pneumoniae, H. influenzae, and M. catarrhalis are commonly isolated respiratory tract infections, with ever-increasing levels of antimicrobial resistance among isolates (4). It is well known that β-lactams have not been useful in treating Legionella infections because of poor penetration into host cells. Thus in vitro activity of L-036 dose not ensure in vivo activity of L-084 agaisnt Legionella infection. Collectively, these data indicate that this novel oral carbapenem has a potentially significant role in the treatment of community-acquired respiratory infections except for Legionella infection.
In general, oral fluoroquinolones and oral expanded-spectrum cephems have been used clinically for the treatment of community-acquired infections. The results indicate that fluoroquinolene-resistant organisms tend to increase with increased use of these agents. In addition, other reports have described extended-spectrum β-lactamaso-producing Enterobacteriaceae isolated from specimens (2, 7). These data indicate that novel antimicrobial agents showing highly potent activity against drug-resistant organisms are needed for patients infected with those organisms.
As stated above, new oral carbapenems have been developed recently. The ED50s of CS-834 and sanfetrinem-cilexetil, when administered orally in mice infected with S. pneumoniae TUH39 twice a day for 3 days or twice a day for 2 days, were 1.78 and 0.18 mg/kg, respectively (15, 20). The former value was similar to, and the latter was 1/10 of, the ED50 of L-084 when this drug was orally administered once. The in vitro activity of L-084 against this strain was 32 times more potent than that of CS-834 and 8 times more potent than that of sanfetrinem-cilexetil. Oral administration of each of these drugs at a dose of 10 mg/kg to mice infected with S. pneumoniae TUM741 three times or twice a day for 3 days produced a differential effect. The number of bacteria recovered from the lungs of mice treated with L-084 was significantly lower than the control, but those from the lungs of mice treated with sanfetrinem-cilexetil and CS-834 were not different from the control. The in vitro activity of L-084 was 8 and 16 times more potent than those of sanfetrinem-cilexetil and CS-834, respectively. When L-084 or CS-834 was administered orally to mice infected with H. influenzae TUM8 at a dose of 20 mg/kg twice a day for 3 days, the percent reduction in the number of viable bacteria in lungs of mice treated with L-084 was a little higher than that in lungs of mice treated with CS-834, and the in vitro activity of L-084 was 8 times more potent than that of CS-834. These results indicate that, in murine respiratory infection models with S. pneumoniae and H. influenzae, the efficacy of L-084 is better than those of other drugs because the in vitro activity of L-084 against infecting organisms is more potent than those of other drugs.
Previous studies have shown that Cmax, t1/2, and AUC of sanfetrinem-cilexetil in lung tissues were 1.94 μg/ml, 0.41 h, and 1.52 μg × h/ml, respectively (15). On the other hand, Cmax and AUC of CS-834 in lung tissues were 0.9 μg/ml and 0.7 μg × h/ml, respectively (20). Our results showed that the Cmax of L-084 was 5 to 10 times higher than those of the above two drugs, that t1/2 of L-084 was 15 times longer than that of sanfetrinem, and that the AUC of L-084 was 20 to 44 times larger than those of the above two drugs. The better pharmacokinetic parameters of L-084 in lungs of mice infected with S. pneumoniae also favor this agent for respiratory infection models.
In conclusion, we have demonstrated in the present study that L-084 is a promising novel oral carbapenem for the treatment of respiratory tract bacterial infections. Our findings for animals need to be confirmed in clinical trials before any conclusions regarding the efficacy of L-084 in human pulmonary infectons can be made.
REFERENCES
- 1.Bootsma H J, Troeltra A, van Veen-Rutgers A, Mooi F R, de Neeling A J, Overbeek B P. Isolation and characterization of a Ciprofloxacin-resistant isolate of Haemophilus influenzae from The Netherlands. J Antimicrob Chemother. 1997;39:292–293. doi: 10.1093/jac/39.2.292. [DOI] [PubMed] [Google Scholar]
- 2.Bush K. Beta-lactamases of increasing clinical importance. Curr Pharm Des. 1999;5:839–845. [PubMed] [Google Scholar]
- 3.Doern G V, Brueggemann A B, Pierce G, Holley H P, Jr, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother. 1997;41:292–297. doi: 10.1128/aac.41.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Felmingham D, Gruneberg R N the Alexander Profect Group. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother. 2000;45:191–203. doi: 10.1093/jac/45.2.191. [DOI] [PubMed] [Google Scholar]
- 5.Georgiou M, Munoz R, Roman F, Canton R, Gomez-Lus R, Campos J, de la Campa A G. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother. 1996;40:1741–1744. doi: 10.1128/aac.40.7.1741. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Hikida M, Itahashi K, Igarashi A, Shiba T, Kitamura M. In vitro antibacterial activity of LJC11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Antimicrob Agents Chemother. 1999;43:2010–2016. doi: 10.1128/aac.43.8.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H. Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A β-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother. 1995;39:2269–2275. doi: 10.1128/aac.39.10.2269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Japanese Society for Chemotherapy. Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by microdilution method. Chemotherapy (Tokyo) 1990;38:102–105. [Google Scholar]
- 9.Japanese Society for Chemotherapy. Method for the determination of minimum inhibitory concentration (MIC) of fastidious bacteria and anaerobic bacteria by microdilution method. Chemotherapy (Tokyo) 1993;41:183–189. [Google Scholar]
- 10.Miyazaki S, Nunoya T, Matsumoto T, Tateda K, Yamaguchi K. New murine model of bronchopneumonia due to cell-bound Haemophilus influenzae. J Infect Dis. 1997;175:205–209. doi: 10.1093/infdis/175.1.205. [DOI] [PubMed] [Google Scholar]
- 11.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing eighth informational supplement. Approved standard M100–S8. Wayne, Pa: National Committee For Clinical Laboratory Standards; 1998. [Google Scholar]
- 12.Spangler S K, Jacobs M R, Appelbaum P C. MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrob Agents Chemother. 1997;41:148–155. doi: 10.1128/aac.41.1.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Seki H, Kasahara Y, Ohta K, Saikawa Y, Sumita R, Yachie A, Fujita S, Koizumi S. Increasing prevalence of ampicillin-resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy. 1999;45:15–21. doi: 10.1159/000007160. [DOI] [PubMed] [Google Scholar]
- 14.Taba H, Kusano N. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes. Antimicrob Agents Chemother. 1998;42:2193–2196. doi: 10.1128/aac.42.9.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Tamura S, Miyazaki S, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N, Yamaguchi K. In vitro antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic. Antimicrob Agents Chemother. 1998;42:1858–1861. doi: 10.1128/aac.42.7.1858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Tanaka M, Hohmura M, Nishi T, Sato K, Hayakawa I. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640. Antimicrob Agents Chemother. 1997;41:1260–1268. doi: 10.1128/aac.41.6.1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Tateda K, Takashima K, Miyazaki H, Matsumoto T, Hatori T, Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBS/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother. 1996;40:1520–1525. doi: 10.1128/aac.40.6.1520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Ubukata K, Asahi Y, Okuzumi K, Konno K the Working Group for Penicillin-Resistant S. pneumoniae. Incidence of penicillin-resistant Streptococcus pneumoniae in Japan, 1993–1995. J Infect Chemother. 1996;1:177–184. doi: 10.1007/BF02350645. [DOI] [PubMed] [Google Scholar]
- 19.Weiss W, Petersen P, Jacobus N, Lin Y, Bitha P, Testa R. In vitro activities of aminomethy-substituted analogs of novel tetrahydrofuranyl carbapenems. Antimicrob Agents Chemother. 1999;43:454–459. doi: 10.1128/aac.43.3.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Yamaguchi K, Domon H, Miyazaki S, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem. Antimicrob Agents Chemother. 1998;42:555–563. doi: 10.1128/aac.42.3.555. [DOI] [PMC free article] [PubMed] [Google Scholar]